definiens: ) is made on the Effective Date ( as defined below ) by and between MITSUBISHI TANABE PHARMA CORPORATION, a corporation with its principal office at 6 - 18, Kitahama 2 - chome, Chuo - ku, Osaka, 541 - 8505, Japan ( hereinafter referred to as ), and [COMPANY] Phannaceuticals, Inc., 640 Lee Road, Chesterbrook, PA 19087 ( hereinafter referred to as ) . MTPC and AUXILIUM are referred to herein individually as and collectively as Whereas, [COMPANY], Inc. ( hereinafter referred to as " [COMPANY] '' ) and MTPC entered into that certain Agreement dated as of December 28, 2000, as amended to date ( the ), under which MTPC has granted to [COMPANY] rights to develop, market and manufacture pharmaceutical products that contain a selective PDE5 INHIBITOR compound referred to by MTPC as and commonly referred to as avanafil ( the " Producf ' )